AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say

Addressing an investor meeting, CFO Bill Chase said Humira should continue strong growth through 2022, while helping leverage the launch and ramp up of successors like risankizumab and upadacitinib.